nine key pharmaceutical

NineKey Pharmaceutical is a clinical-stage biopharmaceutical company focused on developing innovative small molecule drugs for central nervous system (CNS) disorders. The company's lead candidate, NK001, is a highly selective adenosine A2A receptor antagonist currently in Phase 2 clinical trials for the treatment of Parkinson's disease. NineKey's research and development strategy emphasizes high-selectivity and optimized pharmacokinetic profiles to improve safety and efficacy over existing treatments. The company is also advancing a broader pipeline targeting other neurological and psychiatric conditions, including depression and cognitive impairment. NineKey leverages its proprietary CNS discovery platform to identify novel targets and optimize drug candidates for brain penetration and therapeutic impact.